Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells

Blood

Volumn 97, Issue 8, 2001, Pages 2342-2350

  Mahdi, F ^a   Shariat Madar, Z ^a   Todd III, R F ^a   Figueroa, C D ^a   Schmaier, A H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYTOKERATIN; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; UROKINASE RECEPTOR;

ANTIGEN BINDING; ARTICLE; CELLULAR DISTRIBUTION; COMPETITIVE INHIBITION; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 0035871850     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.8.2342     Document Type: Article

References (47)

1. Isolation and characterization of the kininogen binding protein p33 from endothelial cells
2. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "heads" of C1q (gC1q-R)
3. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor
4. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells
5. Mapping binding domains of kininogens on endothelial cell cytokeratin 1
6. Kininogen binding protein p33/gC1qR is localized in the vesicular fraction of endothelial cells
7. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein
8. Intracellular localization of the human receptor for globular domains of C1q
9. Human umbilical vein endothelial cells possess binding sites for the globular head domain of C1q
10. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells
11. Identification of an endothelial cell binding site on kininogen domain D3
12. Mapping the cell binding site on high molecular weight kininogen domain 5
13. Two chain high molecular weight kininogen inhibits endothelial cell proliferation and angiogenesis: Partial activity within domain 5
14. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes
15. 2, CD11 b/CD18) during neutrophil polarization
16. Cleaved high molecular weight kininogen binds directly to the integrin CD 11b/CD18 (Mac-1) and blocks adhesion to fibrinogen and ICAM-1
17. Structure of a gene for the human epidermal 67-kDa keratin
18. Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril
19. High molecular weight kininogen binds to unstimulated platelets
20. Immunologic detection of the cellular receptor for urokinase plasminogen activator
21. Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis
22. Permanent cell line expressing human factor VIII-related antigen established by hybridization
23. Membrane expression of platelet calpain
24. Bradykinin regulates the expression of kininogen binding sites on endothelial cells
25. Periodate-lysine-paraformaldehyde fixative: A new fixative for immunoelectron microscopy
26. Probing for the bradykinin B2 receptor in rat kidney by anti-peptide and anti-ligand antibodies
27. High molecular weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelial cells
28. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells. A novel mechanism for contact activation
29. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation
30. Factor XII does not initiate prekallikrein activation on endothelial cells
31. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator
32. Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment
33. Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes
34. The conserved H1 domain of the type II keratin 1 plays an essential role in the alignment of nearest neighbor molecules in mouse and human keratin 1/keratin10 intermediate filaments at the two- to four-molecule level of structure
35. A leucine to proline mutation in the H1 subdomain of keratin 1 causes epidermolytic hyperkeratosis
36. Mutations in the H1 and 1A domains in the keratin 1 gene in epidemolytic hyperkeratosis
37. Role of urokinase receptor and caveolin in regulation of integrin signaling
38. Looking at lipid rafts
39. Membrane rafts and signaling by the multichain immune recognition receptors
40. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells
41. Regulation of leukocyte adhesion to fibrinogen and endothelial cells by high molecular weight kininogen
42. gC1q-R/p32, a C1q-binding protein, is a receptor for InIB invasion protein of Listeria monocytogenes
43. The expression of high molecular weight kininogen on human umbilical vein endothelial cells
44. Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells
45. The binding of high molecular weight kininogen to cultured human endothelial cells
46. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells
47. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibfts angiogenesis